CN108220420A - A kind of gene marker for being used to diagnose Parkinson - Google Patents
A kind of gene marker for being used to diagnose Parkinson Download PDFInfo
- Publication number
- CN108220420A CN108220420A CN201711484835.9A CN201711484835A CN108220420A CN 108220420 A CN108220420 A CN 108220420A CN 201711484835 A CN201711484835 A CN 201711484835A CN 108220420 A CN108220420 A CN 108220420A
- Authority
- CN
- China
- Prior art keywords
- polr1d
- genes
- parkinsonism
- chip
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
It can be as the diagnostic tool of parkinsonism the invention discloses POLR1D genes.The present invention is known by genetic chip and QPCR researchs, POLR1D genes content in the blood of Parkinson's disease patients is significantly reduced than normal person, and being tested by western blot proves that POLR1D albumen content in the blood of Parkinson's disease patients is significantly reduced than normal person.Therefore POLR1D genes and POLR1D albumen can be as the molecular markers of diagnosis parkinsonism.It is had the advantage that with the content of gene in blood or albumen to characterize parkinsonism：Sample of tissue detection is avoided, alleviates the pain of subject, while the characterizing method can be used for the screening of healthy population, effectively prevent the generation of parkinsonism.
Description
Technical field
The invention belongs to molecular diagnosis fields, are related to a kind of molecular marker for parkinsonism diagnosis, and in particular to
Application of the molecular marker-POLR1D genes in the product for preparing diagnosis parkinsonism in blood.
Background technology
Parkinson's disease (Parkinson Disease, PD) is also known as shaking plasy, is person in middle and old age's nervous system common disease.I
State's epidemiological survey, the illness rate of PD is the 1% (discussion of Luo Yi Primary ventricular hemorrhage drug therapies in 50 years old or more crowd
Liberation army physical-fitness medicine magazine, 2006,8 (1):1-5), men and women's morbidity no significant difference.Domestic and international statistical result is similar.With
The aging of society, it is estimated that the PD incidence to the year two thousand forty will increase by 4 times.The dyskinesia that PD is generated mainly has static
Property is trembled, hypermyotonia, bradykinesia and abnormal posture etc..Often there is neuropsychological obstacle in end-stage disease；It is or a series of
Motor complication.Late period disability is serious, can't take care of oneself, and heavy burden is brought to society and family.However cause PD really
It is still unclear so far to cut etiology and pathogenesis.It is now recognized that it is by inherent cause, environmental factor joint effect, and at the age
Result (Schrag A, Ben-Shlomo Y, Quinn NP.Cross sectional prevalence under the effects that aging
survey of idiopathic Parkinson's disease and Parkinsonism in London[J]
.British Medical Journal.2000,321:21-2；Warner T,Schapira A H.Genetic and
environmental factors in the cause of Parkinson's disease[J].Annals of
Neurology.2003,53(13):16-23).Its major pathologic features are that substantia nigra of midbrain dopaminergic neuron largely loses
It loses, and the inclusion body for having referred to as Lewy body in the nerve cell survived is formed.Lewy body includes the protein of many accumulations
And lipid, wherein α-syn (CooksonMR.The biochemistry of Parkinson's disease as the main component
[J].Annu Rev Biochem.2005,74:29-52).Clinically, diagnosis Parkinson's disease Main Basiss are the clinical conditions of patient
Shape and the experience of doctor there is no the biochemical indicator for assisting in diagnosis Parkinson's disease.At present, research hotspot both domestic and external is transferred to
On the biomarker for studying such degenerative disease, it is desirable to find stability and repeated good biomarker to help
Clinic early diagnosis.For disease, biomarker generally refer to for objective determination and evaluation a generic physiological,
Certain characteristic biochemical indicator in pathology or therapeutic process can know the life that body is presently in by the measure to it
Process during object.More and more researchs find that specific gene can become the biological marker of diagnosis Parkinson
Object, as disclosed in the patent of following application number：201510713527.3、201510464905.9、201510463593.X、
201510463617.1、201510809837.5.Most of disease is all the disease of polygenes regulation and control, in order to improve examining for disease
Lots of genes Combining diagnosis is become inevitable by disconnected accuracy rate, it is therefore desirable to excavate more with the relevant molecular proportion mark of Parkinson's disease
Will object is so as to clinical practice.
Invention content
In order to make up for the deficiencies of the prior art, the purpose of the present invention is to provide one kind can be used for parkinsonism to early diagnose
Molecular marker.Compared to the diagnostic method of traditional parkinsonism, having for parkinsonism is diagnosed using gene marker
Promptness, specificity and sensitivity so as to which patient be made just to know disease risks in disease early stage, for risk height, are taken
Corresponding prevention and treatment measure.
To achieve these goals, the present invention adopts the following technical scheme that：
Application in the tool for diagnosing parkinsonism in preparation the present invention provides the product of detection POLR1D gene expressions.
Further, the product of detection POLR1D gene expressions mentioned above includes：Pass through RT-PCR, real-time quantitative
PCR, immune detection, in situ hybridization, chip or high-flux sequence detection of platform POLR1D gene expression doses are to diagnose Parkinson
The product of disease.
Further, the product with RT-PCR diagnosis parkinsonisms includes at least a pair of of specific amplified POLR1D genes
Primer；The product with real-time quantitative PCR diagnosis parkinsonism includes at least the primer of a pair of of specific amplified POLR1D genes；
The product with immune detection diagnosis parkinsonism includes：The antibody combined with POLR1D protein-specifics；The original position
The product of hybridization diagnosis parkinsonism includes：With the probe of the nucleic acid array hybridizing of POLR1D genes；It is described to diagnose pa with chip
The product of the gloomy disease of gold includes：Protein chip and genetic chip；Wherein, protein chip includes what is combined with POLR1D protein-specifics
Antibody, genetic chip include the probe with the nucleic acid array hybridizing of POLR1D genes.
In specific embodiments of the present invention, the product with real-time quantitative PCR diagnosis parkinsonism includes at least
The sequence of the primer of a pair of of specific amplified POLR1D genes is as shown in SEQ ID NO.1 and SEQ ID NO.2.
Preferably, the diagnostic tool includes chip, kit, test paper or high-flux sequence platform.Wherein, high pass measures
Sequence platform is a kind of special diagnostic tool, and the product of detection POLR1D gene expressions can be applied to platform realization pair
The detection of the expression of POLR1D genes.With the development of high throughput sequencing technologies, to the structure of the gene expression profile of a people
It builds to become and very easily work.By comparing the gene expression profile of Disease and normal population, which easily analyzes
The exception of gene is related to disease.Therefore, know that the exception of POLR1D genes is related to parkinsonism in high-flux sequence
Belong to the purposes of POLR1D genes, equally within protection scope of the present invention.
The present invention also provides a kind of tool for diagnosing parkinsonism, the diagnostic tool includes chip, kit, examination
Paper or high-flux sequence platform.
Wherein, the chip includes genetic chip, protein-chip；The genetic chip includes solid phase carrier and fixation
In the oligonucleotide probe of solid phase carrier, the oligonucleotide probe includes detecting being directed to for POLR1D gene transcription levels
The oligonucleotide probe of POLR1D genes；The protein-chip includes solid phase carrier and is fixed on the POLR1D of solid phase carrier
The specific antibody of albumen；The genetic chip can be used for multiple genes of the detection including POLR1D genes (for example, and pa
The gloomy relevant multiple genes of disease of gold) expression.The protein-chip can be used for detection including POLR1D albumen
The expression of multiple protein (such as with the relevant multiple protein of parkinsonism).By by multiple with parkinsonism mark
Will object detects simultaneously, is greatly improved the accuracy rate of parkinsonism diagnosis.
Wherein, the kit includes gene detecting kit and protein immunization detection kit；The genetic test examination
Agent box includes the reagent for detecting POLR1D gene transcription levels；The protein immunization detection kit includes POLR1D albumen
Specific antibody.Further, the reagent includes the use of RT-PCR, real-time quantitative PCR, immune detection, in situ hybridization or core
Reagent needed for piece method detection POLR1D gene expression dose processes.Preference, the reagent are included for POLR1D bases
The primer and/or probe of cause.It is easily designed according to the nucleotide sequence information of POLR1D genes and can be used for detecting POLR1D
The primer and probe of gene expression dose.
Probe with the nucleic acid array hybridizing of POLR1D genes can be DNA, RNA, DNA-RNA chimera, PNA or other
Derivative.There is no limit for the length of the probe, as long as completing specific hybrid, being specifically bound with purpose nucleotide sequence,
Any length can.The length of the probe can be as short as 25,20,15,13 or 10 bases longs.Equally, the probe
Length can be grown to 60,80,100,150,300 base-pairs or longer or even whole genes.Since different probe lengths is to miscellaneous
Efficiency, signal specificity is handed over to have different influences, the length of the probe is typically at least 14 base-pairs, and longest does not surpass generally
30 base-pairs are crossed, it is best with 15-25 base-pair with the length of purpose nucleotide sequence complementation.The probe self-complementary sequence
Row are most preferably less than 4 base-pairs, in order to avoid influence hybridization efficiency.
The high-flux sequence platform includes the reagent of detection POLR1D gene expression doses.
The test paper includes test paper carrier and the oligonucleotides being fixed on test paper carrier, and the oligonucleotides can detect
The transcriptional level of POLR1D genes.
Further, the specific antibody of the POLR1D albumen includes monoclonal antibody, polyclonal antibody.The POLR1D
The specific antibody of albumen include complete antibody molecule, antibody any segment or modification (for example, chimeric antibody, scFv,
Fab, F (ab ') 2, Fv etc..As long as the segment can retain the binding ability with POLR1D albumen.For protein water
During the preparation of flat antibody well known to a person skilled in the art, and the present invention may use any method it is described anti-to prepare
Body.
In specific embodiments of the present invention, the primer sequence for POLR1D genes is as follows：Forward primer sequence
Row are as shown in SEQ ID NO.1, and reverse primer is as shown in SEQ ID NO.2.
Source for diagnosing the POLR1D genes of parkinsonism and its expression product includes but not limited to blood, tissue
Liquid, urine, saliva, spinal fluid etc. can obtain the body fluid of genomic DNA.In specific embodiments of the present invention, for examining
The POLR1D genes of disconnected parkinsonism and its source of expression product are blood.
In the context of the present invention, any function of " POLR1D genes " including POLR1D genes and POLR1D genes
The polynucleotides of equivalent.POLR1D genes (Chromosome 13, NC_000013.11 (27620743..27667422)) sequence
It is inquired in the international public GenBank GeneBank of Lie Ke.
In the context of the present invention, POLR1D gene expression products include the portion of POLR1D albumen and POLR1D albumen
Divide peptide.The partial peptide of the POLR1D albumen contains and the relevant functional domain of parkinsonism.
Any functional equivalent of " POLR1D albumen " including POLR1D albumen and POLR1D albumen.The function is equal
Object includes POLR1D albumen conservative variation protein or its active fragment or its reactive derivative, allelic variant, natural
Mutant, induced mutants, can be with the encoded protein of DNA of the DNA hybridization of POLR1D under high or low stringent condition.
It is known that, conventionally, the modification of one or more amino acid does not interfere with the function of protein in a protein.
Those skilled in the art can approve the amino acid that changes single amino acids or small percentage or to indivedual additions of amino acid sequence,
Missing, insertion, replacement are conservative modifications, and the change of wherein protein generates the protein with identity function.Function phase is provided
As the Conservative substitution tables of amino acid be well known in the art.
Example by the protein for adding an amino acid or more amino acid modification is melting for POLR1D albumen
Hop protein.For the peptide or protein with POLR1D protein fusions, there is no limit as long as the fusion protein of gained retains
The biological activity of POLR1D albumen.
In the context of the present invention, " diagnosis parkinsonism " had both included judging whether subject has suffered from Parkinson
Disease also includes judging that subject whether there is the risk with parkinsonism.
The advantages of the present invention：
Present invention firstly discovers that POLR1D gene expressions are related to parkinsonism, by detecting POLR1D in subject
Expression, it can be determined that whether subject suffers from parkinsonism or judges that subject whether there is the risk with parkinsonism,
So as to which clinician be instructed to provide prevention scheme or therapeutic scheme to subject.
Present invention finds a kind of new molecular marked compound-POLR1D genes, compared to traditional detection means, gene diagnosis
More in time, it is more special, sensitiveer, the early diagnosis of parkinsonism can be realized, so as to reduce the death rate of parkinsonism.
Description of the drawings
Fig. 1, which is shown, utilizes differential expression of the genechip detection POLR1D genes in Parkinson's disease patients and normal person；
Fig. 2 shows the differential expression in Parkinson's disease patients and normal person using QPCR detection POLR1D genes.
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, such as Sambrook et al., molecular cloning：Laboratory manual (New York:Cold Spring HarborLaboratory
Press, 1989) condition described in or according to the normal condition proposed by manufacturer.
Embodiment 1 screens the gene of differential expression in Parkinson's disease patients and normal person
1st, research object：
Collect primary PD patient 10, man 5, female 5, age 32-85 Sui, the course of disease -20 years 5 months.PD enters a group mark
It is accurate：Diagnostic criteria meets PD clinical criterias (with reference to " Jiang Yuping, Wang Jian, Ding Zhengtong, etc. Primary ventricular hemorrhage is examined
Disconnected standard, 2005, Chinese Clinical Neuscience, 2006,14:40”).Exclusion criteria：(1) essential tremor；(2) secondary pa
The gloomy syndrome of gold；(3) advanced dementia, dysarthrosis person；(4) with other mental disease persons.This studies oneself and passes through hospital's human relations
The reason committee ratifies and all patients sign informed consent form.
Normal group：Choose the healthy volunteer 10 at age 32-80 Sui, each 5 of men and women.
Age, the not statistically significant (P of gender differences between two groups>0.10) it, is comparable.
2nd, in blood total serum IgE extraction
(1) homogenized (Homogenization)
Fresh blood (peripheral blood) is directly taken, 3 times of volume erythrocyte cracked liquids is added in, 10 points is placed at room temperature for after mixing
Clock, 10,000rpm centrifugations 1 minute.It thoroughly inhales and abandons supernatant, collect leukocyte cell pellet.Per the leucocyte of 100-200 μ l blood collections
Precipitation adds in 1ml TRIzol.
(2) it is layered (Phase Separation)
A. after sample adds in TRIzol, 5min is placed at room temperature for, sample is made fully to crack.
B. 200 μ l chloroforms are added in per 1ml TRIzol, 3-5min is placed at room temperature for after shaking vigorously and mix well makes its natural split-phase.
(3) RNA precipitate (RNA Precipitation)
A.4 DEG C 12,000rpm centrifugations 10-15min.Sample can be divided into three layers：The organic phase of yellow, middle layer and colourless
Water phase, RNA mainly in water phase, water phase (can usually draw 550 μ l) are transferred in new pipe.
B. isometric ice-cold isopropanol is added in supernatant, is placed at room temperature for 10-20min.4 DEG C of 12,000rpm centrifugations
10min abandons supernatant, and RNA precipitate is in tube bottom.
(4) RNA rinses (RNA Wash)
75% ethyl alcohol of 1ml (being prepared with RNase-free water) is added in a.RNA precipitations, mildly vibrates centrifuge tube, it is heavy to suspend
It forms sediment.75% ethyl alcohol of 1ml is added in per 1ml TRIzol.
B.4 DEG C 5,000-8,000rpm centrifugation 1-2min, abandon supernatant；Of short duration quick centrifugation is carefully inhaled with pipettor and abandoned
Clearly, 1-2 minutes are placed at room temperature for and dries precipitation.
(5) dissolving RNA (Redissolving the RNA)
50-100 μ l RNase-free water is added in precipitation, flicks tube wall, fully to dissolve RNA, -70 DEG C of preservations.
3rd, RNA mass and purity detecting
RNA mass：It is represented by RNA integralities, plain agar sugar gel electrophoresis (deposition condition can be used：1.2% glue；
0.5 × TBE electrophoretic buffers；150v, 15 minutes) detection integrality.
RNA purity：OD260/OD280 ratios are the indexs for weighing protein contamination degree in RNA sample.High quality
RNA sample, OD260/OD280 values (10mM Tris, pH7.5) are 2.0 or so.
4th, gene chip hybridization and scanning
After the linearized amplification of total serum IgE, cy3-UTP is marked, and the cRNAs after fluorescent marker uses RNEASY Mini Kit
Purifying, fragmentation processing is carried out with the RNA Fragmentation Reagents of Amhion to the cRNAs marked.Using U.S.
People's full genome chip of expression spectrum (4x 44K genes) of Agilent companies of state, 65 DEG C of hybridization 17h in chip hybridization stove, then
Elution, dyeing, finally with Agilent DNA MicroarrayScanner scanner scannings.
5th, chip data processing and analysis
Chip after hybridization imports data to analysis software, for two groups of ratios after chip scanner reads data point
Natural logrithm absolute value be more than 2.0 or the gene less than 0.5 as difference expression gene.
6th, statistical procedures
Data analysis is carried out using 13.0 statistical softwares of SPSS, group difference compares using one-way analysis of variance method, P<
The significant meaning of 0.05 difference.
7th, result
As a result (as shown in Figure 1) is shown, compared with normal person, the mRNA water of POLR1D genes in Parkinson's disease patients blood
Flat to significantly reduce, difference has statistical significance (P<0.05).
The gene of differential expression in 2 QPCR experimental verifications Parkinson's disease patients of embodiment and normal person
1st, research object：
Screening criteria is the same as embodiment 1, Parkinson's disease patients and each 50 of normal person.
2nd, in blood total serum IgE extraction
Step is the same as embodiment 1.
3rd, reverse transcription
Reverse transcription synthesis cDNA is carried out to l μ g total serum IgEs with RT Buffer.Using 25 μ l reaction systems, each sample
1 μ g total serum IgEs is taken to be separately added into following components in PCR pipe as template ribonucleic acid：DEPC water, 5 × RT Buffer,
10mmol/L dNTP, 0.1mmol/l DTT, 30 μm of mol/l Oligo dT, 200U/ μ l M-MLV, template ribonucleic acid.42 DEG C of incubations
1h, 72 DEG C of 10min, of short duration centrifugation.
4、QPCR
(1) design of primers
QPCR amplimers are designed according to the coded sequence of POLR1D genes and GAPDH genes in Genbank, are given birth to by Shanghai
Work biotechnology Services Co., Ltd synthesizes.Specific primer sequence is as follows：
POLR1D genes：
Forward primer is 5 '-GATGAAGTGTCCTCTTGCTA-3 ' (SEQ ID NO.1)；
Reverse primer is 5 '-TTCGCTGGTTCCTTATCG-3 ' (SEQ ID NO.2),
GAPDH genes：
Forward primer is 5 '-TTTAACTCTGGTAAAGTGGATAT-3 ' (SEQ ID NO.3)；
Reverse primer is 5 '-GGTGGAATCATATTGGAACA-3 ' (SEQ ID NO.4).
(2) PCR reaction systems are prepared according to table 1：
Wherein, SYBR Green PCRs system is purchased from Invitrogen companies.
1 PCR reaction systems of table
(3) PCR reaction conditions：95 DEG C of 10min, (95 DEG C of 10s, 60 DEG C of 40s) * 45 cycles.Using SYBR Green as
Fluorescent marker carries out PCR reactions on Light Cycler fluorescence quantitative PCR instruments, true by melt curve analysis analysis and electrophoresis
Determine purpose band, Δ Δ CT methods carry out relative quantification.
5th, statistical method
Result data is represented in a manner of mean+SD, is united using SPSS13.0 statistical softwares
Meter analysis, difference between the two is examined using t, it is believed that works as P<There is statistical significance when 0.05.
6th, result
The results are shown in Figure 2, and compared with normal person, the mRNA level in-site of POLR1D genes is notable in Parkinson's disease patients blood
It reduces, difference has statistical significance (P<0.05), as a result homogenic array experiment.
3 immunoblot experiment of embodiment verifies the expression product of difference expression gene in Parkinson's disease patients and normal person
1st, clinical subjects：With embodiment 2.
2nd, monocyte detaches
Parkinson's disease patients and normal person extracting vein blood 10ml, injection are contained in the sterile vials of heparin, light immediately after capping
Jog is even.Isometric HBSS (NaCl 8.0g, Na are added in aseptic straw2HPO40.132g, KH2PO40.06g, KCl
0.4g, phenol red 1ml, NaHCO30.35g, D-Glucose 1.0g are dissolved in 1000ml distilled waters), to reduce the cohesion of red blood cell.
It draws 8ml lymphocytes separating solutions to put in 50ml centrifuge tubes, dilute blood is slowly added to along tube wall, interface is kept to understand, not
The two is made mutually to mix, 30min, the careful canescence for drawing layering liquid and blood plasma handing-over position muddiness are centrifuged in 20 DEG C of 2000r/min
Layer, i.e. buffy coat are added in another centrifuge tube, and 2 times are washed with the HBSS of 5 times of volumes, successively with 2000r/min,
1500r/min centrifuges 10min at room temperature, the blood platelet largely mixed to remove, with 10ml distilled waters and cell mass
1min is mixed, cracks residual red blood cells, is then rapidly added equivalent 1.8%NaCl solution, supernatant is removed in 2000r/min centrifugations,
Cell is adjusted to 1 × 10 with HBSS solution after cell count6A/ml is spare.
3rd, monocyte gross protein extracts
By cell suspension (a concentration of 1 × 10 obtained by above-mentioned experiment6A/ml) room temperature 1 000r/min centrifugation 10min, abandon
Add in 100 μ l lysis buffers after clear, 4 DEG C of concussion 1h, with ultrasonoscope smudge cells, each 10s, totally 10 times, in 4 DEG C
12000r/min centrifuges 1h；Supernatant Brandford standard measure albumen is taken, is distributed into 2.5 μ g/ μ l, -80 DEG C of refrigerators preserve standby
With.
4th, Western blot are detected
Total protein of cell Brandford standard measures take to mix with sample buffer in right amount and boil 5min, cool down 5min；
30pg albumen is taken to be loaded to 15% polyacrylamide gel prepared, electrophoresis is carried out, starts to be set as 80V constant pressures, see
120V is increased to after Marker；Glue after electrophoresis is taken out, 50min is shifted in 100V using the half-dried transferring systems of Bio.Rad；Turn
It after film, is washed once with 1xPBS, immerses confining liquid, 40C is overnight；Confining liquid is outwelled, adds in Western cleaning solutions washing 5-
10min adds in primary antibody shaking table room temperature hybridization 2h；According to proper proportion Block buffer is diluted in Western secondary antibody diluents
In, it is incubated 60min；Film washing liquid is washed 3 times, each 10min；Developed using ECL reagents, fixing detection protein expression.
5th, statistical procedures
The gray value of protein band is analyzed using Image J softwares, using β-actin as internal reference, by purpose informal voucher
The gray value of band is normalized.Result data is represented in a manner of mean+SD, is used
SPSS13.0 statistical softwares are next for statistical analysis, and difference between the two is examined using t, it is believed that works as P<There is system when 0.05
Meter learns meaning.
6th, result
The results show that using the albumen relative expression levels in normal person's group blood as 1, POLR1D in parkinsonism group blood
Protein level is 0.35 ± 0.08, is significantly increased, and difference has statistical significance (P<0.05).
The explanation of above-described embodiment is only intended to understand the method and its core concept of the present invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will be also fallen into the protection domain of the claims in the present invention.
Sequence table
<110>Beijing Yang Shen biology information technologies Co., Ltd
<120>A kind of gene marker for being used to diagnose Parkinson
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 1
gatgaagtgt cctcttgcta 20
<210> 2
<211> 18
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
ttcgctggtt ccttatcg 18
<210> 3
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 3
tttaactctg gtaaagtgga tat 23
<210> 4
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 4
ggtggaatca tattggaaca 20
Claims (10)
1. detect application of the product of POLR1D gene expressions in the tool for preparing diagnosis parkinsonism.
2. application according to claim 1, which is characterized in that the product includes：By RT-PCR, real-time quantitative PCR,
Immune detection, in situ hybridization, chip or high-flux sequence detection of platform POLR1D gene expression doses are to diagnose parkinsonism
Product.
3. application according to claim 2, which is characterized in that the product with RT-PCR diagnosis parkinsonisms at least wraps
Include the primer of a pair of of specific amplified POLR1D genes；The product with real-time quantitative PCR diagnosis parkinsonism includes at least one
To the primer of specific amplified POLR1D genes；The product with immune detection diagnosis parkinsonism includes：With POLR1D albumen
The antibody of specific binding；The product in situ hybridization diagnosis parkinsonism includes：With the nucleic acid sequence of POLR1D genes
The probe of hybridization；The product with chip diagnosis parkinsonism includes：Protein chip and genetic chip；Wherein, protein chip
Including the antibody combined with POLR1D protein-specifics, genetic chip includes the spy with the nucleic acid array hybridizing of POLR1D genes
Needle.
4. application according to claim 3, which is characterized in that the product with real-time quantitative PCR diagnosis parkinsonism
The primer of a pair of of specific amplified POLR1D genes included at least is as shown in SEQ ID NO.1 and SEQ ID NO.2.
5. a kind of tool for being used to diagnose parkinsonism, which is characterized in that the tool can be by detecting POLR1D in sample
The expression of gene diagnoses parkinsonism.
6. tool according to claim 5, which is characterized in that the tool includes chip, kit, test paper or high throughput
Microarray dataset.
7. tool according to claim 6, which is characterized in that the chip includes genetic chip, protein-chip；It is described
Genetic chip includes solid phase carrier and is fixed on the oligonucleotide probe of solid phase carrier, and the oligonucleotide probe includes being used for
Detect the oligonucleotide probe for POLR1D genes of POLR1D gene transcription levels；The protein-chip is carried including solid phase
Body and be fixed on solid phase carrier POLR1D albumen specific antibody；The kit includes gene detecting kit and egg
White immunity detection reagent；The gene detecting kit includes the reagent for detecting POLR1D gene transcription levels；It is described
Protein immunization detection kit includes the specific antibody of POLR1D albumen；The test paper includes turning for detecting POLR1D genes
Record horizontal reagent；The high-flux sequence platform includes the reagent for detecting POLR1D gene transcription levels.
8. tool according to claim 7, which is characterized in that the reagent of the detection POLR1D gene transcription levels includes
For the primer and/or probe of POLR1D genes.
9. tool according to claim 8, spy are characterized in that, the primer sequence for POLR1D genes is as follows：
Forward primer sequence is as shown in SEQ ID NO.1, and reverse primer is as shown in SEQ ID NO.2.
10. according to the tool described in any one of claim 5-9, which is characterized in that the sample is blood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711484835.9A CN108220420A (en) | 2017-12-29 | 2017-12-29 | A kind of gene marker for being used to diagnose Parkinson |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711484835.9A CN108220420A (en) | 2017-12-29 | 2017-12-29 | A kind of gene marker for being used to diagnose Parkinson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108220420A true CN108220420A (en) | 2018-06-29 |
Family
ID=62647410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711484835.9A Pending CN108220420A (en) | 2017-12-29 | 2017-12-29 | A kind of gene marker for being used to diagnose Parkinson |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108220420A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114264756A (en) * | 2022-01-04 | 2022-04-01 | 宝枫生物科技（北京）有限公司 | Biomarker R1 for diagnosing Parkinson's disease and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105385774A (en) * | 2015-12-24 | 2016-03-09 | 周丽丽 | Application of TMF1 as Parkinsonism diagnosis marker |
| CN105506083A (en) * | 2015-12-24 | 2016-04-20 | 孙梅芬 | Application of CAPG in preparing Parkinsonism diagnosing product |
-
2017
- 2017-12-29 CN CN201711484835.9A patent/CN108220420A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105385774A (en) * | 2015-12-24 | 2016-03-09 | 周丽丽 | Application of TMF1 as Parkinsonism diagnosis marker |
| CN105506083A (en) * | 2015-12-24 | 2016-04-20 | 孙梅芬 | Application of CAPG in preparing Parkinsonism diagnosing product |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114264756A (en) * | 2022-01-04 | 2022-04-01 | 宝枫生物科技（北京）有限公司 | Biomarker R1 for diagnosing Parkinson's disease and application thereof |
| CN114264756B (en) * | 2022-01-04 | 2024-02-06 | 宝枫生物科技（北京）有限公司 | Biomarker R1 for diagnosing parkinsonism and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105400880B (en) | Early diagnosis of acute myocardial infarction marker | |
| CN105543408B (en) | coronary heart disease early diagnosis marker | |
| CN105385774B (en) | Purposes of the TMF1 as parkinsonism diagnosis marker | |
| CN105567861B (en) | Purposes of the IFI27 as diagnosis of coronary heart disease marker | |
| CN108456726A (en) | Spinal muscular atrophy genetic test probe, primer and kit | |
| CN108474038A (en) | The method for assessing systemic inflammatory response syndrome (SIRS) complication for patients risk | |
| CN105907870A (en) | Use of DHX36 as coronary heart disease diagnostic marker | |
| CN107447042A (en) | Molecular marker and its application for diagnostic activities tuberculosis disease | |
| CN108048554B (en) | The molecular marker that THBD gene is diagnosed as parkinsonism | |
| CN108796069A (en) | Diagnosis marker-ING1 the genes of myocardial infarction | |
| CN108034714A (en) | Application of the ARHGAP26 genes in Parkinson's diagnostic tool is prepared | |
| CN108220420A (en) | A kind of gene marker for being used to diagnose Parkinson | |
| CN107904304B (en) | Purposes of the DNASE2 as parkinsonism diagnosis marker | |
| CN108103183B (en) | Novel marker of the KCTD20 genes as early diagnosis parkinsonism | |
| CN108624680B (en) | The application of RAE1 gene or albumen as the biomarker of diagnosing myocardial infarction | |
| CN108220419B (en) | The diagnostic uses of NACC2 gene in blood | |
| CN108796067B (en) | The diagnosis new function of MAEA gene in blood | |
| CN105821152A (en) | Biological marker for coronary heart disease | |
| CN102787163B (en) | Kit for detecting c.1671_1673del G mutation of OTOF gene | |
| CN108300780A (en) | TMTC1 genes are as a kind of new molecular marker | |
| CN110229891A (en) | The product of non-invasive diagnosis Male Osteoporosis | |
| CN110066871A (en) | The early diagnosis marker of hypertensive cerebral hemorrhage | |
| CN108753956A (en) | Application of the KDSR genes in preparing myocardial infarction diagnosis tool | |
| CN108796068A (en) | DOCK10 genes for early diagnosing myocardial infarction | |
| CN101586165A (en) | Kit for detecting 2975-2978delAG mutation of OTOF gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant after: BEIJING MEDINTELL BIOMED Co.,Ltd. Address before: 100080 Beijing city Haidian District Shanyuan Street No. 1 cubic court building room 3103 Applicant before: BEIJING MEDINTELL BIOMED Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191129 Address after: Room 2503, Qianshan building, building D2, Qingdao International Innovation Park Phase II, No. 1, Keyuan Weiyi Road, Laoshan District, Qingdao, Shandong Province Applicant after: Qingdao Yangshen biomedical Co.,Ltd. Address before: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant before: BEIJING MEDINTELL BIOMED Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180629 |
|
| RJ01 | Rejection of invention patent application after publication |